By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ProMetic Life Sciences Inc. 

8168 Montview Road

Mount-Royal  Quebec  H4P 2L7  Canada
Phone: 514-341-2115 Fax: 514-341-6227


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals





Company News
ProMetic Life Sci (PFSCF.PK) To Report Its Fourth Quarter And Year-End 2016 Financial Results And Hold Conference Call / Webcast 3/23/2017 9:36:37 AM
FDA Grants Orphan Drug Designation To ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Drug For The Treatment Of Alström Syndrome 3/3/2017 7:29:11 AM
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Continues To Demonstrate Early Evidence Of Efficacy Following Completion Of Idiopathic Pulmonary Fibrosis Phase II Clinical Trial 2/22/2017 6:28:41 AM
ProMetic Life Sci (PFSCF.PK) Release: Company's PBI-4050 Receives Promising Innovative Medicine Designation From The UK MHRA For The Treatment Of Alström Syndrome 1/24/2017 7:02:51 AM
ProMetic Life Sci (PFSCF.PK) Releaase: European Commission (EC) Grants Orphan Drug Designation To Company's PBI-4050 Drug For The Treatment Of Alström Syndrome 1/18/2017 7:54:11 AM
ProMetic Life Sci (PFSCF.PK) Comments On Unusual Trading Activity 12/19/2016 10:30:10 AM
ProMetic Life Sci (PFSCF.PK) Initiates Rolling Submission Of Its Biologics License Application ("BLA") For Plasminogen With U.S. FDA 12/19/2016 9:54:57 AM
ProMetic Life Sci (PFSCF.PK) Responds To False Market Data Report Regarding Insider Selling 12/9/2016 8:30:05 AM
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Demonstrates Early Evidence Of Efficacy In Its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial 11/17/2016 7:53:00 AM
ProMetic Life Sci (PFSCF.PK) Receives Clearance From Health Canada To Proceed With Its PBI-4050 Placebo-Controlled Phase 2 Clinical Trial In Patients With Metabolic Syndrome And Type 2 Diabetes 11/16/2016 7:48:32 AM
12345678910...
//-->